Francesco Maria Passali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Francesco Maria Passali has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Desiderio Passali
University of Siena
10 shared publications - Stefano Di Girolamo
Department of Otorhinolaryngology, University of Rome Tor Vergata, 00133 Rome, Italy
5 shared publications - Giulio Cesare Passali
Complex Operational Unit of Ear, Nose and Throat Sciences, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy
4 shared publications - Cemal Cingi
Faculty of Medicine, Department of Otorhinolaryngology, Eskisehir Osmangazi University, Eskisehir, Turkey
3 shared publications - Jacopo Cambi
ENT Department Misericordia Hospital Grosseto Italy
3 shared publications Luisa Bellussi
3 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5189
Irreversible Electroporation for the Treatment of Pediatric Adenotonsillar Hypertrophy
Background/Objectives: Irreversible electroporation (IRE) is a non-thermal tissue ablation technology, offering potential advantages such as reductions in pain, bleeding, and procedural time. With this study, we aimed to evaluate the safety and efficacy of IRE for the treatment of adenotonsillar hypertrophy in pediatric patients. Methods: In this prospective, two-center, interventional case series, we enrolled 31 children aged 3–13 years with adenotonsillar hypertrophy and upper airway obstruction. All procedures were performed under general anesthesia. IRE was applied to the tonsils and adenoids using the ENTire™ system. Postoperative pain was recorded daily for seven days using the Parent’s Postoperative Pain Measure. Disease-specific quality of life was assessed at baseline and three months post-procedure using the Obstructive Sleep Apnea questionnaire (OSA-18). Tonsillar size was graded according to the Brodsky Scale. Results: The mean procedure time was 10:40 ± 03:40, and there was no intraoperative or postoperative bleeding. Patients were discharged on the day of the procedure. The postoperative pain on day 1 was ranked as 3.5 ± 1.5 and resolved completely in all patients by day 7. From baseline to 3 months, the mean OSA-18 decreased from 66.4 ± 14.9 to 24.6 ± 9.9 (Wilcoxon signed-rank test p-value of p < 0.001). Conclusions: In this preliminary cohort, non-thermal adenotonsillar ablation using irreversible electroporation was safe, well tolerated, and demonstrated short-term improvements in parent-reported symptoms and oropharyngeal tonsillar size in children. These findings support further investigation in larger, multicenter trials with extended follow-ups.
- 2 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5189
Open AccessIrreversible Electroporation for the Treatment of Pediatric Adenotonsillar Hypertrophy
Background/Objectives: Irreversible electroporation (IRE) is a non-thermal tissue ablation technology, offering potential advantages such as reductions in pain, bleeding, and procedural time. With this study, we aimed to evaluate the safety and efficacy of IRE for the treatment of adenotonsillar hypertrophy in pediatric patients. Methods: In this prospective, two-center, interventional case series, we enrolled 31 children aged 3–13 years with adenotonsillar hypertrophy and upper airway obstruction. All procedures were performed under general anesthesia. IRE was applied to the tonsils and adenoids using the ENTire™ system. Postoperative pain was recorded daily for seven days using the Parent’s Postoperative Pain Measure. Disease-specific quality of life was assessed at baseline and three months post-procedure using the Obstructive Sleep Apnea questionnaire (OSA-18). Tonsillar size was graded according to the Brodsky Scale. Results: The mean procedure time was 10:40 ± 03:40, and there was no intraoperative or postoperative bleeding. Patients were discharged on the day of the procedure. The postoperative pain on day 1 was ranked as 3.5 ± 1.5 and resolved completely in all patients by day 7. From baseline to 3 months, the mean OSA-18 decreased from 66.4 ± 14.9 to 24.6 ± 9.9 (Wilcoxon signed-rank test p-value of p < 0.001). Conclusions: In this preliminary cohort, non-thermal adenotonsillar ablation using irreversible electroporation was safe, well tolerated, and demonstrated short-term improvements in parent-reported symptoms and oropharyngeal tonsillar size in children. These findings support further investigation in larger, multicenter trials with extended follow-ups.
- Open Access
- 24 March 2026
- Published by Springer Nature in Research Square
The Relationship Between Obstructive Sleep Apnea Syndrome and Mood Disorders
Background- We aimed to examine the correlation between the severity of obstructive sleep apnea syndrome (OSAS), measured by the Apnea-Hypopnea Index (AHI), and the severity of mood disorders. Additionally, we evaluated the impact of Continuous Positive Airway Pressure (CPAP) therapy on mood disorder symptoms over a 6-month period. Methods- A total of 60 patients diagnosed with OSAS and treated with CPAP were included in the study. Anxiety and depressive symptoms were assessed using the Beck Anxiety Inventory (BAI) and the Beck Depression Inventory–II (BDI-II), respectively. Polysomnographic parameters, including the AHI, were recorded. Changes in anxiety and depression scores before and after CPAP treatment were analyzed, and the relationship between AHI and mood scores was evaluated. Results- No significant correlation was found between AHI and baseline anxiety or depression scores. Following CPAP treatment, a statistically significant reduction in anxiety and depression scores was observed. In multivariate analysis, AHI was not identified as an independent predictor of baseline anxiety and depression levels. Conclusions- This dissociation highlights the multifactorial nature of mood disturbances in OSAS and supports the notion that psychological symptoms may arise independently of classical polysomnographic severity markers. However, significant reductions in anxiety and depression scores were observed following treatment.
- 24 March 2026
- Published by Springer Nature in Research Square
Open AccessThe Relationship Between Obstructive Sleep Apnea Syndrome and Mood Disorders
Background- We aimed to examine the correlation between the severity of obstructive sleep apnea syndrome (OSAS), measured by the Apnea-Hypopnea Index (AHI), and the severity of mood disorders. Additionally, we evaluated the impact of Continuous Positive Airway Pressure (CPAP) therapy on mood disorder symptoms over a 6-month period. Methods- A total of 60 patients diagnosed with OSAS and treated with CPAP were included in the study. Anxiety and depressive symptoms were assessed using the Beck Anxiety Inventory (BAI) and the Beck Depression Inventory–II (BDI-II), respectively. Polysomnographic parameters, including the AHI, were recorded. Changes in anxiety and depression scores before and after CPAP treatment were analyzed, and the relationship between AHI and mood scores was evaluated. Results- No significant correlation was found between AHI and baseline anxiety or depression scores. Following CPAP treatment, a statistically significant reduction in anxiety and depression scores was observed. In multivariate analysis, AHI was not identified as an independent predictor of baseline anxiety and depression levels. Conclusions- This dissociation highlights the multifactorial nature of mood disturbances in OSAS and supports the notion that psychological symptoms may arise independently of classical polysomnographic severity markers. However, significant reductions in anxiety and depression scores were observed following treatment.
- Open Access
- 7 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 472
The Diabetic Nose: A Narrative Review of Rhinologic Involvement in Diabetes (1973–2025)
Background: Although diabetes mellitus is traditionally viewed as a systemic metabolic disorder, growing evidence indicates that it also affects the upper airways through vascular, inflammatory, and neuro-sensory mechanisms. The sinonasal mucosa, highly vascularized and immunologically active, may represent an early target of diabetic microangiopathy and immune–metabolic imbalance. Objectives: Our objectives are to synthesize current evidence on the rhinologic manifestations of DM, with a focus on chronic rhinosinusitis, olfactory dysfunction, and other nasal disorders, and to identify the main pathophysiologic and clinical patterns linking diabetes to sinonasal disease. Results: Evidence suggests that DM, particularly type 2 DM, increases susceptibility to CRSwNP and modulates the sinonasal microbiome toward Gram-negative predominance. Surgical outcomes after endoscopic sinus surgery are generally comparable between diabetics and non-diabetics when perioperative care is optimized. Olfactory dysfunction occurs more frequently and severely in diabetic patients, likely reflecting the combined effects of chronic inflammation, vascular compromise, and insulin resistance. Additional manifestations include recurrent epistaxis, delayed mucociliary clearance, and chronic cough. Allergic rhinitis appears to not be increased, and maybe even inversely related, especially among users of DPP-4 inhibitors. Conclusions: Diabetes intersects with rhinologic health through immune–metabolic, vascular, and epithelial pathways that may shape susceptibility, disease phenotype, and neurosensory decline. Future research should focus on disentangling type-specific mechanisms, metabolic biomarkers, and longitudinal outcomes, with the aim of developing precision-based approaches to rhinologic assessment and management in diabetic patients.
- 7 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 472
Open AccessThe Diabetic Nose: A Narrative Review of Rhinologic Involvement in Diabetes (1973–2025)
Background: Although diabetes mellitus is traditionally viewed as a systemic metabolic disorder, growing evidence indicates that it also affects the upper airways through vascular, inflammatory, and neuro-sensory mechanisms. The sinonasal mucosa, highly vascularized and immunologically active, may represent an early target of diabetic microangiopathy and immune–metabolic imbalance. Objectives: Our objectives are to synthesize current evidence on the rhinologic manifestations of DM, with a focus on chronic rhinosinusitis, olfactory dysfunction, and other nasal disorders, and to identify the main pathophysiologic and clinical patterns linking diabetes to sinonasal disease. Results: Evidence suggests that DM, particularly type 2 DM, increases susceptibility to CRSwNP and modulates the sinonasal microbiome toward Gram-negative predominance. Surgical outcomes after endoscopic sinus surgery are generally comparable between diabetics and non-diabetics when perioperative care is optimized. Olfactory dysfunction occurs more frequently and severely in diabetic patients, likely reflecting the combined effects of chronic inflammation, vascular compromise, and insulin resistance. Additional manifestations include recurrent epistaxis, delayed mucociliary clearance, and chronic cough. Allergic rhinitis appears to not be increased, and maybe even inversely related, especially among users of DPP-4 inhibitors. Conclusions: Diabetes intersects with rhinologic health through immune–metabolic, vascular, and epithelial pathways that may shape susceptibility, disease phenotype, and neurosensory decline. Future research should focus on disentangling type-specific mechanisms, metabolic biomarkers, and longitudinal outcomes, with the aim of developing precision-based approaches to rhinologic assessment and management in diabetic patients.
- Open Access
- 18 February 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (4) , 433
Pilot Study on the Efficacy of a Novel Questionnaire for Assessing Psychological Health in Patients with Chronic Rhinosinusitis with Nasal Polyps Treated with Biologics
Background/Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a debilitating disease with significant morbidity and decreased quality of life (QoL). The introduction of biologics in its management has allowed new therapeutic options, and Dupilumab represents the first approved biologic. This study aims to evaluate a possible relationship between the clinical response to biological therapy and mental health in patients with severe CRSwNP. Methods: This is a multicenter study conducted at the Otolaryngology departments of three major Italian health institutions. Participants were patients with CRSwNP treated with Dupilumab. Patients were assessed at baseline and during treatment by submitting them to a survey consisting of a dedicated questionnaire focused on psychological health and two patient-reported outcome measures (PROMs): the 22-item Sino-Nasal Outcome Test (SNOT-22) and a Visual Analogue Scale (VAS) for nasal symptoms. Results: 86 patients were included in the study (58 males and 28 females; mean age: 58.2 years). There was a significant improvement in both symptoms and QoL, with an enhanced psychological state observed in patients after the first administration and within the first months of therapy. Conclusions: This study evaluated the possible correlations between Dupilumab treatment and improvements in mental health in patients with CRSwNP, as assessed through a survey, and clinical conditions, assessed through SNOT-22 and VAS. Our findings showed that Dupilumab not only improved clinical symptoms but also had a positive impact on patients’ mental health, with benefits observed already after the first administration and the first months of therapy. This survey highlights the relevance of psychological well-being and its implications for patients with chronic diseases such as CRSwNP.
- 18 February 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (4) , 433
Open AccessPilot Study on the Efficacy of a Novel Questionnaire for Assessing Psychological Health in Patients with Chronic Rhinosinusitis with Nasal Polyps Treated with Biologics
Background/Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a debilitating disease with significant morbidity and decreased quality of life (QoL). The introduction of biologics in its management has allowed new therapeutic options, and Dupilumab represents the first approved biologic. This study aims to evaluate a possible relationship between the clinical response to biological therapy and mental health in patients with severe CRSwNP. Methods: This is a multicenter study conducted at the Otolaryngology departments of three major Italian health institutions. Participants were patients with CRSwNP treated with Dupilumab. Patients were assessed at baseline and during treatment by submitting them to a survey consisting of a dedicated questionnaire focused on psychological health and two patient-reported outcome measures (PROMs): the 22-item Sino-Nasal Outcome Test (SNOT-22) and a Visual Analogue Scale (VAS) for nasal symptoms. Results: 86 patients were included in the study (58 males and 28 females; mean age: 58.2 years). There was a significant improvement in both symptoms and QoL, with an enhanced psychological state observed in patients after the first administration and within the first months of therapy. Conclusions: This study evaluated the possible correlations between Dupilumab treatment and improvements in mental health in patients with CRSwNP, as assessed through a survey, and clinical conditions, assessed through SNOT-22 and VAS. Our findings showed that Dupilumab not only improved clinical symptoms but also had a positive impact on patients’ mental health, with benefits observed already after the first administration and the first months of therapy. This survey highlights the relevance of psychological well-being and its implications for patients with chronic diseases such as CRSwNP.
- 26 November 2023
- Published by Springer Nature
- p. 545-550
Sleep Apnea Syndrome in Elderly
- 11 November 2023
- Published by Springer Nature
- p. 857-869
COVID-19 in Children and Hearing Loss
- Open Access
Correction: Guerrieri et al. Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection. Vaccines 2021, 9, 1499
The authors wish to make the following corrections to this paper
Open AccessCorrection: Guerrieri et al. Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection. Vaccines 2021, 9, 1499
The authors wish to make the following corrections to this paper
- 29 July 2022
- Published by Springer Nature
- p. 65-76
Functional Diagnostic Tools in Rhinoplasty: Italian Experience
- 29 July 2022
- Published by Springer Nature
- p. 65-76
Functional Diagnostic Tools in Rhinoplasty: Italian Experience